Patient-reported outcomes in support of oncology product labeling claims: regulatory context and challenges

References

• Dooms CA, Pat KE, Vansteenkiste JF. The effect of chemotherapy on symptom control and quality of life in patients with advanced non-small-cell lung cancer. Expert Rev. Anticancer Ther.6(4), 531–544 (2006).
   PubMed Web of Science ®Google Scholar
• Hassan I, Cima RC, Sloan JA. Assessment of quality of life outcomes in the treatment of advanced colorectal malignancies. Gastroenterol. Clin. North Am.35, 53–64 (2006).
   PubMed Web of Science ®Google Scholar
• Chandu A, Smith AC, Rogers SN. Health-related quality of life in oral cancer: a review. J. Oral Maxillofac. Surg.64, 495–502 (2006).
   PubMed Web of Science ®Google Scholar
• Blazeby JM, Avery K, Sprangers M, Pikhart H, Fayers P, Donovan J. Health-related quality of life measurement in randomized clinical trials in surgical oncology. J. Clin. Oncol.24, 3178–3186 (2006).
   PubMed Web of Science ®Google Scholar
• Efficace F, Bottomley A, Osoba D et al. Beyond the development of health-related quality-of-life (HRQOL) measures: a checklist for evaluating HRQOL outcomes in cancer clinical trials – does HRQOL evaluation in prostate cancer research inform clinical decision making? J. Clin. Oncol.21, 3502–3511 (2003).
   PubMed Web of Science ®Google Scholar
• Bottomley A, Efficace F, Thomas R, Vanvoorden V, Ahmedzai SH. Health-related quality of life in non-small-cell lung cancer: methodologic issues in randomized controlled trials. J. Clin. Oncol.21, 2982–2992 (2003).
   PubMedGoogle Scholar
• Buchanan DR, O’Mara AM, Kelaghan JW, Minasian LM. Quality-of-life assessment in the symptom management trials of the National Cancer Institute – supported community clinical oncology program. J. Clin. Oncol.23, 591–598 (2005).
   PubMed Web of Science ®Google Scholar
• Rock EP, Scott JA, Kennedy DL, Sridhara R, Pazdur R, Burke LB. Challenges to use of health-related quality of life for Food and Drug Administration approval of anticancer products. J. Natl Cancer Inst. Monogr.37, 27–30 (2007).
   Google Scholar
• European Medicines Agency. Reflection Paper on the Regulatory Guidance for the Use of Health-Related Quality of Life (HRQL) Measures in the Evaluation of Medicinal Products. European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), London, UK (2005).
   Google Scholar
• Gotay CC, Lipscomb J, Snyder CF. Reflections on findings of the cancer outcomes measurement working group: moving to the next phase. J. Natl Cancer Inst.97(21), 1568–1574 (2005).
   PubMed Web of Science ®Google Scholar
• Johnson JR, Williams G, Pazdur R. End points and United States Food and Drug Administration approval of oncology drugs. J. Clin. Oncol.21(7), 1404–1411 (2003).
   PubMed Web of Science ®Google Scholar
• Food and Drug Administration. Guidance For Industry: Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics. MD, USA (2007).
   Google Scholar
• Williams G, Pazdur R, Temple R. Assessing tumor-related signs and symptoms to support cancer drug approval. J. Biopharm. Stat.14(1), 5–21 (2004).
   PubMedGoogle Scholar
• Berrino F, Gatta G, Chessa E, Valente F, Capocaccia R. The Eurocare Working Group Introduction: the Eurocare II study. Eur. J. Cancer34, 2139–2153 (1999).
   Google Scholar
• Coleman MP. Opinion: why the variation in breast cancer survival in Europe? Breast Cancer Res.1, 22–26 (1999).
   PubMedGoogle Scholar
• Levi F, Lucchini F, Negri E, La Vecchia C. The decline in cancer mortality in the European Union, 1988–1996. Eur. J. Cancer36, 1965–1968 (2000).
   PubMed Web of Science ®Google Scholar
• Apolone G, Joppi R, Bertele V, Garattini S. Ten years of marketing approvals of anticancer drugs in Europe: regulatory policy and guidance documents need to find a balance between different pressures. Br. J. Cancer93, 504–509 (2005).
   PubMed Web of Science ®Google Scholar
• Weng CSW. Where is health-related quality-of-life assessment in oncology clinical study heading? J. Biopharm. Stat.14, 1–3 (2004).
   PubMedGoogle Scholar
• Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K. The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J. Palliat. Care7, 6–9 (1991).
   PubMedGoogle Scholar
• De Haes JC, van Knippenberg FC, Neijt JP. Measuring psychological and physical distress in cancer patients: structure and application of the Rotterdam Symptom Checklist. Br. J. Cancer62, 1034–1038 (1990).
   PubMed Web of Science ®Google Scholar
• Ware JE Jr, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med. Care30(6), 473–483 (1992).
   PubMed Web of Science ®Google Scholar
• Aaronson NK, Ahmedzai S, Bergman B et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality of life instrument for use in international trials in oncology. J. Natl Cancer Inst.85, 365–376 (1993).
   PubMed Web of Science ®Google Scholar
• Cella DF, Tulsky DS, Gray G et al. The functional Assessment of Cancer Therapy scale: development and validation of the general measure. J. Clin. Oncol.11, 570–579 (1993).
   PubMed Web of Science ®Google Scholar
• Hollen PJ, Gralla RJ, Kris MG et al. Measurement of quality of life in patients with lung cancer in multicenter trials of new therapies: psychometric assessment of the Lung Cancer Symptom Scale. Cancer73, 2087–2098 (1993).
   Google Scholar
• Lindley CM, Hirsch JD, O’Neil CV et al. Quality of life consequences of chemotherapy-induced emesis. Qual. Life Res.1, 331–340 (1992).
   PubMedGoogle Scholar
• Bacik J, Mazumdar M, Murphy BA et al. The functional assessment of cancer therapy-BRM (FACT-BRM): a new tool for the assessment of quality of life in patients treated with biologic response modifiers. Qual. Life Res.13, 137–154 (2004).
   PubMed Web of Science ®Google Scholar
• Sprangers MA, Groenvold M, Arraras JI et al. The European Organization for Research and Treatment of Cancer breast cancer-specific quality of life questionnaire module: first results from a three-country field study. J. Clin. Oncol.14, 2756–2768 (1996).
   PubMed Web of Science ®Google Scholar
• Calhoun EA, Change CH, Welshman EE et al. A neutropenia-specific quality of life instrument: rationale for the development of the FACT N. Proc. Annu. Meet. Am. Assoc. Cancer Res.21, 375a. (2002) (Abstract 1498).
   Google Scholar
• Doroshow JH. Restructuring the National Cancer Clinical Trials Enterprise: Clinical Trials Working Group Implementation Update. Presented at: Patient-Reported Outcomes Assessment in Cancer Trials: Evaluating and Enhancing the Payoff to Decision Making. MD, USA, 20–21 September 2006.
   Google Scholar
• Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Suport Labeling Claims, Draft Guidance. MD, USA (2006).
   Google Scholar
• Food and Drug Administration. Guidance for Industry: Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims. MD, USA (2009).
   Google Scholar
• Johnson JR, Temple R. Food and Drug Administration requirements for approval of new anti-cancer drugs. Cancer Treat. Rep.69, 1155–1159 (1985).
   PubMedGoogle Scholar
• O’Shaughnessy JA, Wittes RE, Burke G et al. Commentary concerning demonstration of safety and efficacy of investigational anticancer agents in clinical trials. J. Clin. Oncol.9, 2225–2232 (1991).
   PubMed Web of Science ®Google Scholar
• Rock EP, Kennedy DL, Furness MH, Pierce WF, Pazdur R, Burke LB. Patient-reported outcomes supporting anticancer product approvals. J. Clin. Oncol.25(32), 5094–5099 (2007).
   PubMed Web of Science ®Google Scholar
• Acquadro C, Berzon R, Dubois D et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health6, 522–531 (2003).
   PubMed Web of Science ®Google Scholar
• Leidy NK, Revicki DA, Geneste B. Recommendations for evaluating the validity of quality of life claims for labeling and promotion. Value Health2, 113–127 (1999).
   PubMedGoogle Scholar
• Revicki DA, Osoba D, Fairclough D et al. Recommendations on health-related quality of life research to support labeling and promotional claims in the United States. Qual. Life Res.9, 887–900 (2000).
   PubMed Web of Science ®Google Scholar
• Chassany O, Sagnier P, Marquis P et al. For the European Regulatory Issues on Quality of Life Assessment Group. Patient-reported outcomes: the example of health-related quality of life – a European guidance document for the improved integration of health-related quality of life assessment in the drug regulatory process. Drug Inf. J.36, 209–218 (2002).
   Web of Science ®Google Scholar
• Papanicolaou S, Sykes D, Mossialos E. EMEA and the evaluation of health-related quality of life data in the drug regulatory process. Int. J. Technol. Assess. Health Care20(3), 311–324 (2004).
   PubMedGoogle Scholar
• Szende A, Leidy NK, Revicki D. Health-related quality of life and other patient-reported outcomes in the European Centralized Drug Regulatory Process: a review of guidance documents and performed authorizations of medicinal products 1995 to 2003. Value Health8(5), 534–548 (2005).
   PubMedGoogle Scholar
• European Medicines Agency. Evaluation of Anticancer Medicinal Products in Man (CPMP/EWP/205/95 rev.3). European Medicines Agency, Committee for Medicinal Products for Human Use (CHMP), London, UK (2006).
   Google Scholar
• Kaplan RM. The significance of quality of life in health care. Qual. Life Res.12(Suppl. 1), 3–16 (2003).
   PubMed Web of Science ®Google Scholar
• Willke RJ, Burke LB, Erickson P. Measuring treatment impact. A review of patient-reported outcomes and other efficacy endpoints in approved product labels. Control. Clin. Trials25, 535–552 (2004).
   PubMedGoogle Scholar
• Bottomley A, Jones D, Claassens L. Patient-reported outcomes: assessment and current perspectives of the guidelines of the Food and Drug Administration and the reflection paper of the European Medicines Agency. Eur. J. Cancer45, 347–353 (2009).
   PubMed Web of Science ®Google Scholar
• Little RJ. Modeling the drop-out mechanism in repeated-measures studies. J. Am. Stat. Assoc.90, 1112–1121 (1995).
   Web of Science ®Google Scholar
• Leon A, Mallinckrodt C, Chuang-Stein C, Archibald D, Archer G, Chartier K. Attrition in randomized controlled clinical trials: methodological issues in psychopharmacology biological psychiatry. Biol. Psychiatry59(11), 1001–1005 (2006).
   PubMed Web of Science ®Google Scholar
• Given B, Given CW, Sikorskii A, You M, McCorkle R, Champion V. Analyzing symptom management trials: the value of both intention-to-treat and per-protocol approaches. Oncol. Nurs. Forum36(6), E293–E302 (2009).
   PubMedGoogle Scholar
• Sloan JA, Dueck AC, Erickson PA, Guess H, Revicki DA, Santanello NC. Analysis and interpretation of results based on patient-reported outcomes: the Mayo/FDA Patient-Reported Outcomes Consensus Meeting Group. Value Health10(Suppl. 2), S106–S115 (2007).
   PubMedGoogle Scholar
• Crawford B, Burke L. Meeting the US FDA’s evidence standard with health-related quality of life claims. Expert Rev. Pharmacoeconomics Outcomes Res.2(5), 401–402 (2002).
   PubMedGoogle Scholar
• Holm S. A simple sequentially rejective multiple test procedure. Scand. J. Stat.6, 65–70 (1979).
   Web of Science ®Google Scholar
• Hochberg Y. A sharper Bonferroni procedure for multiple tests of significance. Biometrika75, 800–802 (1988).
   Web of Science ®Google Scholar
• Fairclough DL. Summary measures and statistics for comparison of quality of life in a clinical trial of cancer therapy. Stat. Med.16, 1197–1209 (1997).
   PubMed Web of Science ®Google Scholar
• Sloan JA, Dueck A. Issues for statisticians in conducting analyses and translating results for quality of life end points in clinical trials. J. Biopharm. Stat.14, 73–96 (2002).
   Google Scholar
• Stevens J. Applied Multivariate Statistics for the Social Sciences (3rd Edition). Lawrence Erlbaum Associates, NJ, USA (1996).
   Google Scholar
• Mosconi P, Fossati R, Confalonieri C, Apolone G. Breast cancer and quality of life: controversial points of view. Tumori2, S53–S54 (2003).
   Google Scholar